APA (7th ed.) Citation

Oar, A., Lee, M., Le, H., Wilson, K., Aiken, C., Chantrill, L., . . . Goldstein, D. (2021). AGITG MASTERPLAN: A randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer, 21(1), 1. https://doi.org/10.1186/s12885-021-08666-y

Chicago Style (17th ed.) Citation

Oar, Andrew, et al. "AGITG MASTERPLAN: A Randomised Phase II Study of Modified FOLFIRINOX Alone or in Combination with Stereotactic Body Radiotherapy for Patients with High-risk and Locally Advanced Pancreatic Cancer." BMC Cancer 21, no. 1 (2021): 1. https://doi.org/10.1186/s12885-021-08666-y.

MLA (9th ed.) Citation

Oar, Andrew, et al. "AGITG MASTERPLAN: A Randomised Phase II Study of Modified FOLFIRINOX Alone or in Combination with Stereotactic Body Radiotherapy for Patients with High-risk and Locally Advanced Pancreatic Cancer." BMC Cancer, vol. 21, no. 1, 2021, p. 1, https://doi.org/10.1186/s12885-021-08666-y.